An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Inclusion Criteria:

• Participants who completed the end of treatment visit in Study INS1009-211 (NCT05176951). Participants for whom the OLE study was not available at the time oftheir completion of the lead-in study are eligible for enrolment within one year oftheir lead-in end of treatment visit.

• Complete baseline screening assessments to confirm eligibility to participate ifmore than 30 days have elapsed since the end of the study visit in StudyINS1009-211, or any other lead-in PH-ILD TPIP study.

• Capable of giving signed informed consent that includes compliance with therequirements and restrictions listed in the informed consent form (ICF) and in thisprotocol.

Exclusion Criteria:

• Participants who experienced any hypersensitivity or adverse drug reaction or werewithdrawn early/discontinued in a previous PH-ILD TPIP study, which in the opinionof the Investigator, could indicate that continued treatment with TPIP may presentan unreasonable risk for the participant.

• Initiation of parenteral administration of prostacyclin analogues (eg, TRE,epoprostenol) since the completion of Study INS1009-211 or other TPIP studies.Initiation of inhaled prostacyclin analogues (eg, TRE [Tyvaso] or iloprost) and oralprostacyclin analogues (eg, TRE [Orenitram]) or receptor agonists (eg, selexipag)are permitted if stopped 24 hours prior to the start of study drug administration.

Pregnant or breastfeeding. Male and female participants must use contraceptives that are consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Female participants of childbearing potential must have a negative urine pregnancy test result at trial entry before the first dose of study drug.

• Any medical or psychological condition, including relevant laboratory abnormalities at screening that, in the opinion of the Investigator, suggest a new and/or insufficiently understood disease that may present an unreasonable risk to the study participant as a result of participation in the study.